Children's Center for Cancer and Blood Diseases, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, The Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California; Organizing Committee, National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2013 Nov;19(11):1534-6. doi: 10.1016/j.bbmt.2013.08.016. Epub 2013 Sep 10.
Despite advances in hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies, relapse remains the leading cause of death after transplant. Biologic and clinical investigations are needed to combat this primary cause of death after transplantation. The National Cancer Institute held international workshops in 2009 and 2012 to help address this problem. Three major initiatives for coordinated research were proposed: 1) To establish multicenter networks for basic, translational, epidemiologic and clinical research; 2) To establish a network of biorepositories for the collection of samples before and after HSCT to aid in laboratory and clinical studies; and 3) To refine, implement and study proposed definitions for disease-specific response and relapse and for monitoring of minimal residual disease. The workshop in 2012 also featured nine presentations, summaries of which follow in three manuscripts.
尽管造血干细胞移植(HSCT)在治疗血液系统恶性肿瘤方面取得了进展,但移植后复发仍是导致死亡的主要原因。需要进行生物学和临床研究来对抗移植后这一主要死亡原因。美国国家癌症研究所于 2009 年和 2012 年举办了国际研讨会,以帮助解决这一问题。提出了三项协调研究的主要倡议:1)建立用于基础、转化、流行病学和临床研究的多中心网络;2)建立生物库网络,在 HSCT 前后收集样本,以辅助实验室和临床研究;3)完善、实施和研究针对疾病特异性反应和复发以及最小残留疾病监测的建议定义。2012 年的研讨会还包括 9 个专题介绍,以下是其中 3 篇专题介绍的摘要。